Third Harmonic Bio

Third Harmonic Bio

Biotechnology, 300 Technology Sq, Cambridge, Massachusetts, 02139, United States, 11-50 Employees

thirdharmonicbio.com

  • twitter
  • LinkedIn

phone no Phone Number: 16*********

Who is THIRD HARMONIC BIO

Third Harmonic Bio is a clinical-stage company developing a highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts...

Read More

map
  • 300 Technology Sq, Cambridge, Massachusetts, 02139, United States Headquarters: 300 Technology Sq, Cambridge, Massachusetts, 02139, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from THIRD HARMONIC BIO

Third Harmonic Bio Org Chart and Mapping

Employees

Timothy Thullen

Executive Director of Nonclinical Development

Michael Turner

Executive Director of Immunology

Julie Person

Chief Administrative Officer

Nam Doan

Senior Director, IT

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Third Harmonic Bio

Answer: Third Harmonic Bio's headquarters are located at 300 Technology Sq, Cambridge, Massachusetts, 02139, United States

Answer: Third Harmonic Bio's phone number is 16*********

Answer: Third Harmonic Bio's official website is https://thirdharmonicbio.com

Answer: Third Harmonic Bio's revenue is $1 Million to $5 Million

Answer: Third Harmonic Bio's SIC: 2834

Answer: Third Harmonic Bio has 11-50 employees

Answer: Third Harmonic Bio is in Biotechnology

Answer: Third Harmonic Bio contact info: Phone number: 16********* Website: https://thirdharmonicbio.com

Answer: Third Harmonic Bio is a clinical-stage company developing a highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the bodys interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. Our lead product candidate, THB001, is the first highly selective, oral small-molecule KIT inhibitor to enter clinical development. With promising drug-like properties and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access